Loading
JK08 is an experimental fusion protein or cytokine from Salubris Biotherapeutics in phase 2 trials for melanoma, colorectal cancer and non-small-cell lung cancer, aimed at CTLA-4.
JK08 is a fusion protein or cytokine developed by Salubris Biotherapeutics. Its target is CTLA-4. ClinicalTrials.gov describes the intervention as: Recombinant fusion protein consisting of two functional elements, which are a fully human monoclonal antibody, directed against CTLA-4 and a protein complex formed by the human IL-15 and the Sushi domain of human IL-15Rα. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in melanoma, colorectal cancer, non-small-cell lung cancer, bladder & urothelial cancer and head and neck squamous cell carcinoma. The largest, NCT05620134, plans to enrol 263 participants with primary completion was scheduled for 2025-10-17 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Fusion protein or cytokine directed at CTLA-4, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated. Connects to CTLA-4.
1.JK08 binds CTLA-4.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"JK08" OR ABSTRACT:"JK08") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about JK08, not a curated reading list.
Shares Renal cell carcinoma, Bladder & urothelial cancer, Head and neck squamous cell carcinoma, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Ovarian cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares CTLA-4, Renal cell carcinoma, Bladder & urothelial cancer, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Bladder & urothelial cancer, Hepatocellular carcinoma, Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Bladder & urothelial cancer, Head and neck squamous cell carcinoma, Pancreatic ductal adenocarcinoma, Colorectal cancer and the tag pipeline.
Shares Renal cell carcinoma, Head and neck squamous cell carcinoma, Triple-negative breast cancer (TNBC), Colorectal cancer and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer, Head and neck squamous cell carcinoma, Ovarian cancer, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer, Head and neck squamous cell carcinoma, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.